Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This Phase 3 multinational, randomized, double-blind study is designed to compare the
efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo
in subjects with MCL.